New bifunctional device actuator for nasal and buccal drug administration of new products, existing products, life cycle extension opportunities and franchising

Font Standard Bold
Login

Research unit

INNOSUISSE

Project number

13748.1;7 PFFLE-LS

Project title

New bifunctional device actuator for nasal and buccal drug administration of new products, existing products, life cycle extension opportunities and franchising

Texts for this project

	German	French	Italian	English
Short description	-	-	-
Abstract	-	-	-

Inserted texts

Category	Text
Short description (English)	New bifunctional device actuator for nasal and buccal drug administration of new products, existing products, life cycle extension opportunities and franchising
Abstract (English)	Application of drugs to the mucosa of the upper airways is a frequent medical need. The goal of this project is to develop a new bifunctional device actuator for combined nasal and buccal drug administration. The new device will have additional benefits such as easy handling, pervasive drug distribution and better patient compliance. This device offers Bioforce AG significant production cost reductions and enhanced marketing opportunities as well as product life cycle extensions. Overall, an additional sales volume of CHF 2.6 Mio per year after product launch is expected.

Category

Text

Short description
(English)

New bifunctional device actuator for nasal and buccal drug administration of new products, existing products, life cycle extension opportunities and franchising

Abstract
(English)

Application of drugs to the mucosa of the upper airways is a frequent medical need. The goal of this project is to develop a new bifunctional device actuator for combined nasal and buccal drug administration. The new device will have additional benefits such as easy handling, pervasive drug distribution and better patient compliance. This device offers Bioforce AG significant production cost reductions and enhanced marketing opportunities as well as product life cycle extensions. Overall, an additional sales volume of CHF 2.6 Mio per year after product launch is expected.